The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete.

The reader should not assume that the information is accurate and complete.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM D

Notice of Exempt Offering of Securities

OMB APPROVAL OMB 3235-Number: 0076 Estimated average burden hours per response: 4.00

1. Issuer's Identity

CIK (Filer ID Number)	Previous Names	None	Entity Type	
<u>0001402479</u>	Rough Tide Marine Operations, Inc.		c. X Corporation	
Name of Issuer	Marvin's Place, Inc.		Limited Partnership	
Atlas Therapeutics Corp			Limited Liability Company	
Jurisdiction of			General Partnership	
Incorporation/Organizatio	n		Business Trust	
NEVADA			Other (Specify)	
Year of Incorporation/O	rganization			
Over Five Years Ago				
X Within Last Five Years (Specify	Year) 2007			
Yet to Be Formed				
2. Principal Place of Business and C	Contact Information			
Name of Issu	er			
Atlas Therapeutics Corp				
Street Addres	s 1		Street Address 2	
520 S. EL CAMINO REAL, 8TH F	FLOOR			
-	te/Province/Country	ZIP/PostalCo	ode Phone Number of Issuer	
SAN MATEO CALI	FORNIA	94402	213-291-1847	
3. Related Persons				
Last Name	Firs	st Name	Middle Name	
Bernstein	J.B.			
Street Address 1	Street	Address 2		
520 S. El Camino Real, 8th Floor				
City	State/Prov	vince/Country	ZIP/PostalCode	
San Mateo	CALIFORNIA	9	94402	
Relationship: X Executive Officer	X Director Promot	er		
Clarification of Response (if Necess	sary):			
Last Name	Firs	st Name	Middle Name	
Colker, MD, FACN	Carlon			
Street Address 1	Street	Address 2		
520 S. El Camino Real, 8th Floor				
City	State/Prov	vince/Country	ZIP/PostalCode	
San Mateo	CALIFORNIA	-	94402	
Relationship: X Executive Officer	Director Promote	2r		

Clarification of Response (if Necessary):

Last Name	First Name	Middle Name
Mathers	Georgette	
Street Address 1	Street Address 2	
520 S. El Camino Real, 8th Flo	or	
City	State/Province/Country	ZIP/PostalCode
San Mateo	CALIFORNIA	94402
Relationship: Executive Offi		
Clarification of Response (if Ne	cessary):	

4. Industry Group

Agriculture Banking & Financia Commercial Ban Insurance Investing Investment Bank Pooled Investment Is the issuer regis an investment co the Investment Co Act of 1940?	king ing nt Fund stered as mpany under	Health Care Biotechnology Health Insurance Hospitals & Physicians Pharmaceuticals X Other Health Care Manufacturing Real Estate Commercial	Retailing Restaurants Technology Computers Telecommunications Other Technology Travel Airlines & Airports
Yes	No	Construction	Lodging & Conventions Tourism & Travel Services
Other Banking &	Financial Services	REITS & Finance	Other Travel
Business Services		Residential	Other
Energy		Other Real Estate	
Coal Mining			
Electric Utilities			

Environmental Services

Energy Conservation

- Oil & Gas
- Other Energy

5. Issuer Size

Revenue Range	OR	Aggregate Net Asset Value Range
X No Revenues		No Aggregate Net Asset Value
\$1 - \$1,000,000		\$1 - \$5,000,000
\$1,000,001 - \$5,000,000		\$5,000,001 - \$25,000,000
\$5,000,001 - \$25,000,000		\$25,000,001 - \$50,000,000
\$25,000,001 - \$100,000,000		\$50,000,001 - \$100,000,000
Over \$100,000,000		Over \$100,000,000
Decline to Disclose		Decline to Disclose
Not Applicable		Not Applicable

6. Federal Exemption(s) and Exclusion(s) Claimed (select all that apply)

Rule 504(b)(1) (not (i), (ii) or (iii))
Rule 504 (b)(1)(i)
Rule 504 (b)(1)(ii)
Rule 504 (b)(1)(iii)

Rule 505 X Rule 506 Securities Act Section 4(5) Investment Company Act Section 3(c) Section 3(c)(1) Section 3(c)(9)

Se Se Se	ection 3(c)(2 ection 3(c)(3 ection 3(c)(4 ection 3(c)(5 ection 3(c)(6 ection 3(c)(7)	3) 4) 5)	Section $3(c)(10)$ Section $3(c)(11)$ Section $3(c)(12)$ Section $3(c)(13)$ Section $3(c)(14)$	
7. Type of Filing				
X New Notice Date of First Sale 2011-02-25 First S Amendment	Sale Yet to C	Dccur		
8. Duration of Offering				
Does the Issuer intend this offering to last more than on	ie year?	Yes X No		
9. Type(s) of Securities Offered (select all that apply)				
X Equity Debt X Option, Warrant or Other Right to Acquire Another S X Security to be Acquired Upon Exercise of Option, W Other Right to Acquire Security		Tenant-in	vestment Fund Interests -Common Securities roperty Securities scribe)	
10. Business Combination Transaction				
Is this offering being made in connection with a busines a merger, acquisition or exchange offer?	ss combinati	ion transac	tion, such as X Yes No	
Clarification of Response (if Necessary):				
Please see the Issuer's Form 8-K filed with the SEC on I	EDGAR on	March 3, 2	011.	
11. Minimum Investment				
Minimum investment accepted from any outside investo	or \$0 USD			
12. Sales Compensation				
Recipient	Recipie	ent CRD N	umber X None	
(Associated) Broker or Dealer X None	(Assoc	iated) Brol	er or Dealer CRD Number X None	<u>د</u> -
Street Address 1			Street Address 2	
City	State/Pr	rovince/Co	untry	ZIP/Postal Code
State(s) of Solicitation (select all that apply) Check "All States" or check individual States	ites Forei	gn/non-US	;	
13. Offering and Sales Amounts				
Total Offering Amount \$2,500,000 USD or Inde	finite			
Total Amount Sold \$1,430,000 USD				
Total Remaining to be Sold \$1,070,000 USD or Inde	finite			
Clarification of Response (if Necessary):				
14. Investors				
Select if securities in the offering have been or may h	ba sold to pa	arcone who	do not qualify as accredited	

Select if securities in the offering have been or may be sold to persons who do not qualify as accredited investors, and enter the number of such non-accredited investors who already have invested in the offering. Regardless of whether securities in the offering have been or may be sold to persons who do not qualify as

4

accredited investors, enter the total number of investors who already have invested in the offering:

15. Sales Commissions & Finder's Fees Expenses

Provide separately the amounts of sales commissions and finders fees expenses, if any. If the amount of an expenditure is not known, provide an estimate and check the box next to the amount.

Sales Commissions	\$0 USD	Estimate
Finders' Fees	\$0 USD	Estimate

Clarification of Response (if Necessary):

16. Use of Proceeds

Provide the amount of the gross proceeds of the offering that has been or is proposed to be used for payments to any of the persons required to be named as executive officers, directors or promoters in response to Item 3 above. If the amount is unknown, provide an estimate and check the box next to the amount.

\$450,000 USD Estimate

Clarification of Response (if Necessary):

Consideration for assets purchased from seller who simultaneously became an executive officer of the Issuer.

Signature and Submission

Please verify the information you have entered and review the Terms of Submission below before signing and clicking SUBMIT below to file this notice.

Terms of Submission

In submitting this notice, each issuer named above is:

- Notifying the SEC and/or each State in which this notice is filed of the offering of securities described and undertaking to furnish them, upon written request, in the accordance with applicable law, the information furnished to offerees.*
- Irrevocably appointing each of the Secretary of the SEC and, the Securities Administrator or other legally designated officer of the State in which the issuer maintains its principal place of business and any State in which this notice is filed, as its agents for service of process, and agreeing that these persons may accept service on its behalf, of any notice, process or pleading, and further agreeing that such service may be made by registered or certified mail, in any Federal or state action, administrative proceeding, or arbitration brought against the issuer in any place subject to the jurisdiction of the United States, if the action, proceeding or arbitration (a) arises out of any activity in connection with the offering of securities that is the subject of this notice, and (b) is founded, directly or indirectly, upon the provisions of: (i) the Securities Act of 1933, the Securities Exchange Act of 1934, the Trust Indenture Act of 1939, the Investment Company Act of 1940, or the Investment Advisers Act of 1940, or any rule or regulation under any of these statutes, or (ii) the laws of the State in which the issuer maintains its principal place of business or any State in which this notice is filed.
- Certifying that, if the issuer is claiming a Rule 505 exemption, the issuer is not disqualified from relying on Rule 505 for one of the reasons stated in Rule 505(b)(2)(iii).

Each Issuer identified above has read this notice, knows the contents to be true, and has duly caused this notice to be signed on its behalf by the undersigned duly authorized person.

For signature, type in the signer's name or other letters or characters adopted or authorized as the signer's signature.

Issuer	Signature	Name of Signer	Title	Date
Atlas Therapeutics Corp	/s/ J.B. Bernstein	J.B. Bernstein	Chief Executive Officer	2011-03-08

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

* This undertaking does not affect any limits Section 102(a) of the National Securities Markets Improvement Act of 1996 ("NSMIA") [Pub. L. No. 104-290, 110 Stat. 3416 (Oct. 11, 1996)] imposes on the ability of States to require information. As a result, if the securities that are the subject of this Form D are "covered securities" for purposes of NSMIA, whether in all instances or due to the nature of the offering that is the subject of this Form D, States cannot routinely require offering materials under this undertaking or otherwise and can require offering materials only to the extent NSMIA permits them to do so under NSMIA's preservation of their anti-fraud authority.